The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...
The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...
The US price for Sanofi's rival PCSK9 inhibitor Praluent (alirocumab) is $14,600 a year – pricing for the European market has yet to be revealed – but analysts have suggested the class as a ...
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
imperial.ac.uk Within this review we look at whether the potential provided by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition for prevention of atherosclerotic cardiovascular disease ...
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.
DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback